ORTX Orchard Therapeutics plc

-0.34  -2%
Previous Close 14.11
Open 14.1
Price To Book 3.57
Market Cap 1,324,474,610
Shares 96,185,520
Volume 130,076
Short Ratio
Av. Daily Volume 230,148

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented February 24, 2019.
X-linked chronic granulomatous disease (X-CGD)
Phase 1/2 engraftment data due 2019.
Adenosine deaminase severe combined immunodeficiency (ADA-SCID)
Phase 1/2 data presented April 29, 2019.
Transfusion-dependent beta-thalassemia (TDBT)
Phase 2 presentation at SSIEM September 4, 2019.
Metachromatic leukodystrophy (MLD)
Phase 1/2 three-year follow up data due by end of 2019.
Wiskott-Aldrich Syndrome (WAS)

Latest News

  1. It’s not just Bloom Energy: Half of last year’s Bay Area IPO stocks are underwater
  2. Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
  3. Orchard Therapeutics plc (ORTX) Q2 2019 Earnings Call Transcript
  4. Orchard Therapeutics Reports Second Quarter 2019 Financial Results and Builds Momentum Ahead of Regulatory Filings
  5. Orchard Therapeutics to Webcast Presentation at the 2019 Wedbush PacGrow Healthcare Conference
  6. Orchard Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for OTL-103 for the Treatment of Wiskott-Aldrich Syndrome
  7. Hedge Funds Have Never Been This Bullish On Orchard Therapeutics plc (ORTX)
  8. Orchard Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference on June 12, 2019
  9. The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering
  10. Orchard Therapeutics Announced Pricing of Public Offering
  11. Orchard Therapeutics Launches Proposed Public Offering
  12. Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
  13. Orchard Therapeutics Announces Expansion of Neurometabolic Disease Portfolio and Reports First Quarter 2019 Financial Results
  14. Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele Announce Exclusive Worldwide License Agreement for the Treatment of MPS-I
  15. Orchard Therapeutics to Webcast Conference Call of First Quarter 2019 Financial Results on May 28, 2019
  16. Orchard Therapeutics Announces Clinical Proof-of-Concept Data for Gene Therapy OTL-300 Demonstrating Efficacy in Transfusion-Dependent Beta-Thalassemia
  17. Orchard Therapeutics Strengthens Commercial Leadership Team with Appointment of Francis Pang as Vice President of Global Market Access
  18. Orchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
  19. Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting